Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level

被引:119
作者
Hiuge, Aki
Tenenbaum, Alexander
Maeda, Norikazu
Benderly, Michal
Kumada, Masahiro
Fisman, Enrique Z.
Tanne, David
Matas, Zipora
Hibuse, Toshiyuki
Fujita, Koichi
Nishizawa, Hitoshi
Adler, Yehuda
Motro, Michael
Kihara, Shinji
Shimomura, Iichiro
Behar, Solomon
Funahashi, Tohru
机构
[1] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan
[2] Neufeld Cardiac Res Inst, Chaim Sheba Med Ctr, Cardiac Rehabil Inst, Israel Soc Prevent Heart Attacks,Bezafibrate Infa, Tel Hashomer, Israel
[3] Wolfson Med Ctr, Biochem Lab, Holon, Israel
关键词
adipocyte; adiponectin; fibrate; metabolic syndrome; peroxisome proliferator-activated receptor;
D O I
10.1161/01.ATV.0000256469.06782.d5
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective - Adiponectin is adipose-specific secretory protein and acts as anti-diabetic and anti-atherosclerotic molecule. We previously found peroxisome proliferators response element in adiponectin promoter region, suggesting that peroxisome proliferator-activated receptor (PPAR) ligands elevate adiponectin. Fibrates are known to be PPAR alpha ligands and were shown to reduce risks of diabetes and cardiovascular disease. Effect of fibrates on adiponectin has not been clarified, whereas thiazolidinediones enhance adiponectin. Thus, we explored the possibility and mechanism that fibrates enhance adiponectin in humans, mice, and cells. Methods and Results - Significant increase of serum adiponectin was observed in bezafibrate-treated subjects compared with placebo group in patients enrolled in The Bezafibrate Infarction Prevention study. Higher baseline adiponectin levels were strongly associated with reduced risk of new diabetes. Fibrates, bezafibrate and fenofibrate, significantly elevated adiponectin levels in wild-type mice and 3T3-L1 adipocytes. Such an effect was not observed in PPAR alpha-deficient mice and adipocytes. Fibrates activated adiponectin promoter but failed to enhance its activity when the point mutation occurred in peroxisome proliferators response element site and the endogenous PPAR alpha was knocked down by PPAR alpha-RNAi. Conclusions - Our results suggest that fibrates enhance adiponectin partly through adipose PPAR alpha and measurement of adiponectin might be a useful tool for searching subjects at high risk for diabetes.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 26 条
[1]
Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes [J].
Blaschke, F ;
Takata, Y ;
Caglayan, E ;
Law, RE ;
Hsueh, WA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) :28-40
[2]
Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats [J].
Choi, KC ;
Ryu, OH ;
Lee, KW ;
Kim, HY ;
Seo, JA ;
Kim, SG ;
Kim, NH ;
Choi, DS ;
Baik, SH ;
Choi, KM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 336 (03) :747-753
[3]
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[4]
The role of fibric acids in atherosclerosis. [J].
Fruchart J.C. ;
Staels B. ;
Duriez P. .
Current Atherosclerosis Reports, 2001, 3 (1) :83-92
[5]
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α) [J].
Guzmán, M ;
Lo Verme, J ;
Fu, J ;
Oveisi, F ;
Blázquez, C ;
Piomelli, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :27849-27854
[6]
Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors [J].
Iwaki, M ;
Matsuda, M ;
Maeda, N ;
Funahashi, T ;
Matsuzawa, Y ;
Makishima, M ;
Shimomura, I .
DIABETES, 2003, 52 (07) :1655-1663
[7]
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].
Keech, A ;
Simes, RJ ;
Barter, P ;
Best, J ;
Scott, R ;
Taskinen, MR ;
Forder, P ;
Pillai, A ;
Davis, T ;
Glasziou, P ;
Drury, P ;
Kesäniemi, YA ;
Sullivan, D ;
Hunt, D ;
Colman, P ;
d'Emden, M ;
Whiting, M ;
Ehnholm, C ;
Laakso, M .
LANCET, 2005, 366 (9500) :1849-1861
[8]
Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor γ [J].
Kishida, K ;
Shimomura, I ;
Nishizawa, H ;
Maeda, N ;
Kuriyama, H ;
Kondo, H ;
Matsuda, M ;
Nagaretani, H ;
Ouchi, N ;
Hotta, K ;
Kihara, S ;
Kadowaki, T ;
Funahashi, T ;
Matsuzawa, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) :48572-48579
[9]
Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose [J].
Knobler, H ;
Benderly, M ;
Boyko, V ;
Behar, S ;
Matas, Z ;
Rubinstein, A ;
Raz, I ;
Wainstein, J .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 154 (01) :87-92
[10]
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia [J].
Koh, KK ;
Ahn, JY ;
Han, SH ;
Shin, EK ;
Quon, MJ .
DIABETES CARE, 2005, 28 (06) :1419-1424